非感染性葡萄膜炎非皮质类固醇全身免疫调节治疗指南:葡萄膜炎基础照护(FOCUS)倡议
国际专家主导的共识倡议,采用系统综述与改良德尔菲法制定非感染性葡萄膜炎非皮质类固醇全身免疫调节治疗推荐。共10个临床问题、21条循证指导声明,涵盖治疗启动时机、治疗前数据收集、调整或停药、药物选择及特定葡萄膜炎类型的证据。
要点
- 共形成21条循证指导声明,覆盖非感染性葡萄膜炎非皮质类固醇免疫调节治疗的10个临床问题。
- 声明涉及治疗启动时机、治疗前数据收集、调整或停药、基于疗效与安全性选择药物及特定类型证据。
- 推荐还包括共享决策、提供者间沟通与安全性监测;药物经济学考量未涉及。
核心结论
- 基于已发表文献、专家意见和实践经验制定共识指南,以弥合临床需求与医学证据之间的差距,支持非感染性葡萄膜炎患者使用非皮质类固醇免疫调节剂治疗。
研究设计与样本
- 国际专家指导委员会由9名葡萄膜炎专家(包括眼科医生和风湿科医生)组成,确定临床问题。
- 与6名受过葡萄膜炎培训的文献研究员共同按照PRISMA方案进行系统综述,检索1996年1月至2016年6月的英文文献,数据库包括Medline(OVID)、Cochrane中央图书馆、EMBASE、CINAHL、SCOPUS、BIOSIS和Web of Science。
- 纳入随机对照试验、随访充分的前瞻性和回顾性研究、病例数≥15例的病例系列、同行评议文章及关键会议的手工检索会议摘要。
- 拟议声明在130名国际葡萄膜炎专家中传阅评审;2016年末44名全球代表性组成员开会,采用改良德尔菲技术完善指南并分配牛津证据等级。
主要发现
- 共处理10个问题,形成21条循证指导声明,涵盖何时启动非皮质类固醇免疫调节治疗(包括生物制剂和非生物制剂)。
- 声明还涵盖治疗前应收集哪些数据、何时调整或停止治疗、如何根据个体疗效和安全性特征选择药物以及特定葡萄膜炎类型的证据。
- 推荐还涉及共享决策、提供者之间的沟通以及安全性监测;药物经济学考量未涉及。
关键数值与推荐
- 采用牛津证据等级对推荐进行分级;共21条循证指导声明,基于10个临床问题。
- 系统综述检索1996年1月至2016年6月的英文文献;纳入病例系列要求≥15例。
- 拟议声明由130名国际葡萄膜炎专家评审,44名组成员参与改良德尔菲法完善。
临床怎么用
- 指南旨在支持非感染性葡萄膜炎患者使用非皮质类固醇全身免疫调节剂的治疗决策。
- 推荐涉及治疗启动时机、治疗前数据收集、治疗调整或停药、基于个体疗效与安全性选择药物。
- 推荐包括共享决策、提供者间沟通和安全性监测。
局限性
- 药物经济学考量未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. CLINICAL RELEVANCE: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. METHODS: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. RESULTS: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. CONCLUSIONS: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.
引用
- Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative. Ophthalmology. 2018. PMID: 29310963. doi:10.1016/j.ophtha.2017.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。